Yu-Kyeong Hwang
Cell Therapy Research Center, Green Cross Lab Cell Corp., South Korea
Biography
Yu Kyeong Hwang has worked in pharmaceutical company driven research institute for more than 25 years. Her main interest is immune activation by antigen stimulation, many of candidate peptides and DNA constructs were listed in patents. Based on long term experience of cellular immunology in T cell area, since 2014, she is a Director of Cell Therapy Research Center in Green Cross LabCell (GCLC) Corp. By developing NK cell therapeutics, she controlled all process from discovery to clinical trials of ex vivo expanded allogeneic NK cell which was the world’s first clinical trial. In the clinical trial phase I, she discovered the mechanism of allogeneic NK cell after infusion into patients. Currently this NK cell program goes on phase IIa against HCC. Another couple of clinical trials are preparing IND submission in Korea and US.